Seeking Alpha

Isis Pharmaceuticals (ISIS +3.1%) clearly has something that Biogen Idec (BIIB +1.3%) likes -...

Isis Pharmaceuticals (ISIS +3.1%) clearly has something that Biogen Idec (BIIB +1.3%) likes - the latter adds a third agreement in the companies' partnership, which will now include the development of drugs for three undisclosed targets to treat neurological or neuromuscular disorders. Biogen will pay Isis $30M upfront, another $200M in milestones for each program, and double-digit royalties on drug sales. (PR)
Comments (1)
  • arthurs1
    , contributor
    Comments (343) | Send Message
     
    Get in now! Great DD can be found here.
    http://bit.ly/JC0uFl
    10 Dec 2012, 11:11 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|